Get 3D InSight™ at SLAS2016
The annual conference of the Society of Laboratory Automation and Screening is where science research and development professionals gather to learn about the lastest and greatest laboratory tools and technologies available and how they are being applied by their peers. If you're interested in 3D microtissue technology for drug discovery and development or disease modeling, InSphero will be hosting several educational events you won't want to miss.
Screen with greater relevance in 3D
Are you screening in 3D? InSphero can help you begin or advance your screening in organotypic 3D models with solutions to ASSAY, IMAGE, and AUTOMATE in 3D. Visit one of our presentations or find us at Booth #307 to gain 3D InSight™ from our experts in microtissue technology:
• Assay-ready 3D InSight™ Microtissues – standardized 3D models and optimized medium delivered conveniently to your lab, ready to screen
• 3D InSight™ Services – let our experts test your compounds in our proprietary 3D models with standard and custom service offerings
• Technical Protocols - refer to our 3D optimized assay protocols to learn how to make the most of your investment in microtissues
• Scaffold-free 3D cell culture platforms – reliable ultra-low attachment and hanging drop platforms for automated microtissue production and assay
Your 3D InSight™ Conference Planner
23. - 27. January 2016
San Diego Convention Center
Meet InSphero 3D microtissue experts at Booth #307
Before the Conference
Watch our on-demand webinars to gain 3D Insight™ and make notes on questions to ask while you're at SLAS2016
Saturday, January 23, 8:30 AM - 4:30 PM
Register for a short course: 3D Cell-based Assays for Drug De-Risking led by Drs. Jens Kelm of InSphero, Ursula Graf-Hausner of the University of Applied Sciences Zurich, and Terry Riss of Promega Corporation
Monday, January 25, 1:00 - 3:00 PM
Visit Poster #2057: Multi-parametric 3D tumor microtissue-based phenotypic compound classification by Dr. Jens Kelm of InSphero (co-authored by NCATS/NIH). Poster Abstract: Phenotypic assays are a powerful tool in drug discovery. However, the predictive value of phenotypic drug testing depends on how close we can mimic the in vivo environment and the biomarker used to assess the clinical response. The closer we mimic the tissue environment and the respective disease progression the better the predictive value of an assay to discover and develop new therapeutics. 3D model systems can better reflect the cell composition, inter-cellular interaction, tissue structure, and biological characteristics of primary tumors. Here, we report on the development of homo- and heterotypic ovarian and pancreatic microtissue tumor models amenable for a screening assay of up to 40 compounds selected from the NCATS Oncology library. The compounds were chosen to target different mechanisms driving tumor cell growth and survival. The goal of this study was to develop a high throughput compatible drug screening assay based on 3D multicellular spheroids from ovarian (HEY-A8 and SKOV) and pancreatic (Panc-1) cancer which enables the discrimination of tumor-specific efficacy and unspecific cytotoxicity of a drug candidate with subsequent identification of the molecular mechanism of action (MMOA). The biological response measured over a 10-day drug exposure period included (i) growth kinetics (microtissue size), (ii) potency (IC50ATP_10_days) and efficacy (max. response ATP and size). The biological response of the compounds was compared between the different cell culture formats tested, 2D, 3D homotypic and 3D heterotypic. The comparison of IC50 values among the different ovarian cancer cell cultures showed that 21 out of the 38 compounds tested were more potent in 3D than in 2D. Within the pancreatic models, 13 out of 20 compounds tested were more potent in 3D than in 2D. Interestingly, most of the compounds which showed stronger potency in 3D were targeted small molecule agents. Comparing drug responses of homo vs heterotypic ovarian tumor model systems, 3 compounds were effective only in the heterotypic model including the WNT inhibitor PNU-74654 and GABA uptake inhibitor (Gat-1) SK&F-89976A. We also evaluated non-specific cytotoxic effects on the incorporated NIH3T3 fibroblasts by quantifying a secreted reporter over time. The assay system allowed us to discriminate between acute cytotoxic effects (3-day exposure) and sub-chronic toxicity (7-day exposure). Whereas only a very limited number of compounds had acute cytotoxic effects, there were considerable more compounds with sub-chronic cytotoxicity. Based on the single endpoint classifications, we choose an mTOR inhibitor, Torin-2, to further assess molecular mechanism of cell death action for all three tumor microtissue models used in this study using reversed phase protein assay and transcriptome analysis. In summary, we present a 3D tumor microtissue-based phenotypic drug discovery testing scheme which allows a multi-parametric endpoint analysis paired with subsequent molecular pathway identification.
Monday, January 25, 1:00 - 3:00 PM
Visit Poster #2189: Simplifying 3D microtissue-based screening using automation and image based cytometry on the EnSight multimode plate reader to generate and characterize scaffold-free 3D cell cultures, by Ann (Shang-pin) Kwei of PerkinElmer. Poster Abstract: 3D cell culture spans the gap between the traditional “petri-dish-based” format and whole-animal systems by both mimicking features of the in vivo environment and taking advantage of the same tools used to study cells in traditional cell culture, thus giving unique perspectives on tumorigenesis. Process standardization is essential to enable the generation of robust and reproducible data with more biologically relevant, but complex, 3D models. Here we demonstrate how producing and characterizing 3D spheroid microtissues with the InSphero GravityPLUS™ hanging drop microplate platform can be simplified and standardized by integrating automated liquid handlers with the EnSight™Multimode plate reader to reduce variability, hands-on time, and errors produced by manual pipetting. Process steps include: (i) using automation to generate hanging drop cultures in the InSphero GravityPLUS™ plate, (ii) automated transfer of the hanging drop cultures to the GravityTRAP™ ultra-low attachment plates for long-term growth, and (iii) automated media exchange and compound treatment in these plates. Tumor microtissue growth was assessed directly in the GravityTRAP™ plate using the imaging module of the EnSight™ plate reader and a custom-developed analysis procedure for basic 2D characterization that automatically identifies and measures spheroid area from brightfield images. This allows for rapid monitoring of tumor microtissue growth over time without necessitating addition of a fluorescent label. Tissue viability and proliferation was assessed further using the ATPlite™Luminescence Assay system in which spheroids are thoroughly lysed and ATP content assessed. Overall, a fully automated microtissue production and assay set-up is being presented to monitor growth and viability to further foster the use of more biologically relevant 3D models on an industrial scale.
Monday, January 25, 2:00 - 2:45 PM
Attend a tutorial: High-throughput, label-free phenotypic screening of tumor spheroid growth and morphology (featuring the SCREEN Cell 3iMager), led by Dr. Leena Mol Thuruthippallil of InSphero
Tuesday, January 26, 2:00 - 2:45 PM
Attend a tutorial: Advances in drug testing using scaffold-free 3D cell culture in automated high content screening systems, led by Dina Sirypangno of InSphero and Jacob Tesdorpf of PerkinElmer
Learn from our experience — and win a Sphero 2.0!